Oncologist投稿须知

期刊简介

《Oncologist》是由AlphaMed Press出版社于1996年创办的英文国际期刊（ISSN: 1083-7159，E-ISSN: 1549-490X），该期刊长期致力于肿瘤学领域的创新研究，主要研究方向为医学-肿瘤学。作为SCIE收录期刊（JCR分区 Q1，中科院 2区），本刊采用OA未开放获取模式（OA占比%），以发表肿瘤学领域等方向的原创性研究为核心（研究类文章占比87.07%%）。凭借严格的同行评审与高效编辑流程，期刊年载文量精选控制在317篇，确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库，为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Oncologist审稿周期约为一般,3-8周。该刊近年未被列入国际预警名单，年发文量约317篇，录用竞争适中，主题需确保紧密契合医学前沿。投稿策略提示：避开学术会议旺季投稿以缩短周期，语言建议专业润色提升可读性。

医学大类学科
English 出版语言
否是否预警
SCIE 期刊收录
317 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊	综述期刊	大类学科	小类学科
是	否	医学 2区	ONCOLOGY 肿瘤学 2区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊	综述期刊	大类学科	小类学科
否	否	医学 2区	ONCOLOGY 肿瘤学 2区

JCR分区

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	70 / 322	78.4%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	76 / 322	76.55%

CiteScore

SJR

SNIP

CiteScore 排名

CiteScore：10.4

SJR：1.991

SNIP：1.487

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q1	55 / 404	86%
大类：Medicine 小类：Cancer Research	Q1	47 / 230	79%

期刊发文

Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
Author: Cheng, Xingyuan; Chen, Baoqing; Wang, Sifen; Zhang, Jun; Zhu, Jinhan; Liu, Mengzhong; Liu, Shiliang; Xi, Mian

Journal: ONCOLOGIST. 2023; Vol. , Issue , pp. -. DOI: 10.1093/oncolo/oyad094
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
Author: She, Lei; Gong, Xuan; Su, Lin; Liu, Chao

Journal: ONCOLOGIST. 2023; Vol. 28, Issue 1, pp. E45-E53. DOI: 10.1093/oncolo/oyac202
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
Author: Toi, Masakazu; Boyle, Frances; Im, Young-Hyuck; Reinisch, Mattea; Molthrop, David; Jiang, Zefei; Wei, Ran; Sapunar, Francisco; Grimes, Brenda R.; Nabinger, Sarah Cassidy; Johnston, Stephen R. D.

Journal: ONCOLOGIST. 2023; Vol. 28, Issue 1, pp. E77-E81. DOI: 10.1093/oncolo/oyac234
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
Author: Wei, Xiao-Li; Zhang, Yang; Zhao, Hong-Yun; Fang, Wen-Feng; Luo, Hui-Yan; Qiu, Miao-Zhen; He, Ming-Ming; Zou, Ben-Yan; Xie, Jie; Jin, Chun-Lei; Zhou, Xian-Feng; Wang, Feng; Wang, Feng-Hua; Li, Yu-Hong; Wang, Zhi-Qiang; Xu, Rui-Hua

Journal: ONCOLOGIST. 2023; Vol. 28, Issue 1, pp. E36-E44. DOI: 10.1093/oncolo/oyac225
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
Author: Liu, Yin; Fan, Lei; Wang, Zhong-Hua; Shao, Zhi-Ming

Journal: ONCOLOGIST. 2023; Vol. 28, Issue 1, pp. 86-+. DOI: 10.1093/oncolo/oyac223
The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms
Author: Liu, Man; Li, Na; Tang, Hongzhen; Chen, Luohai; Liu, Xuemei; Wang, Yu; Lin, Yuan; Luo, Yanji; Wei, Shaozhen; Wen, Wenli; Chen, Minhu; Wang, Jiaqian; Zhang, Ning; Chen, Jie

Journal: ONCOLOGIST. 2023; Vol. , Issue , pp. -. DOI: 10.1093/oncolo/oyad093
Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study
Author: Zhao, Lulu; Fu, Yongliang; Niu, Penghui; Zhang, Fan; Jiao, Fuzhi; Zhou, Xiadong; Wu, Zhenkun; Wang, Wanqing; Luan, Xiaoyi; Han, Xue; He, Mingyan; Guan, Quanlin; Li, Yumin; Zhao, Dongbing; Gao, Jidong; Chen, Yingtai

Journal: ONCOLOGIST. 2023; Vol. , Issue , pp. -. DOI: 10.1093/oncolo/oyad108
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
Author: Li, Xiaomi; Ding, Xiaoyan; Liu, Mei; Wang, Jingyan; Li, Wei; Chen, Jinglong

Journal: ONCOLOGIST. 2023; Vol. , Issue , pp. -. DOI: 10.1093/oncolo/oyad107

Oncologist

肿瘤学家

期刊简介

投稿提示

中科院分区

JCR分区

CiteScore

期刊发文

相关期刊

怎样选择期刊

投稿相关问题

投稿后咨询